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CHIRAL DRUGS: ONE DRUG OR TWO? 
Clinical pharmacology through the looking glass: 
reflections on the racemate vs enantiomer debate 
J. Mifsud 
ABSTRACT 
Most of the synthetic chiral agents administered as drugs are still marketed as 
racemic mixtures. Such drug enantiomers can differ substantially in their 
pharmacological, pharmacokinetic and toxic properties. The development of 
enantiomerically pure drugs would lead to better therapeutic indices, and less 
complex interactions. Thus, the re-realisation of the importance of stereochemistry 
in pharmacology has an important contribution to make to the development and use 
of safer and more effective medicines. The impact of chirality on drug development 
and registration policies is discussed. 
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INTRODUCTION The accepted nomenclature today is the (R)/(S) 
system which is related to the Cahn-Ingold­
"Perhaps, looking glass milk isn't good to drink" Prelog Convention. Labetolol is just one of a 
- Lewis Carroll in Alice in Wonderland number of chiral drugs and it has two chiral 
centres. 
If told by their doctor that they were being 
prescribed tablets containing 50% of an impurity 
o 11 CII.that is toxic or at best inactive, most patients 
11 Oil /11 "'" / .
would no doubt be horrified. This hypothetical 11 , '<- (, C
"'" C' 
state of affairs may seem somewhat bizarre, but x;( ",,,,,,/.,, ''' '''''---Cthe impression that the therapeutic use of drug 
racemates is harmful, has certainly gained ground Oil 
in medical circles over the last few years. 
Figure 11 - The chemical structure of labetolol.Racemates are 50/50 mixtures of the left and 
*:chiral centres
right-handed forms or enantiomers of 
compounds, whose molecular structure lack 
symmetry because the central carbon atoms is Without actually being aware of it, chirality has 
sUlTounded by four different atoms or groups of been with us since the beginning of time. The 
atoms. universe, at its most fundamental level, is 
handed, being made up of molecules, sugars, 
amino acids whose stereochemistry is absolutely 
RI RI defined. Enantiomers have identical physical and 
chemical properties in an nonchiral environment,I IR -----c " - R, _ Rc - c/' -----R.j~ 
R, R, 
Figure I - The chiral carbon and its two mirror images Janet Mifsud B. Pharm (Hons) 
Assistant Lecturer,This phenomenon is called chirality - coming 
Dept ofPharmacy,from the greek word "cherios" which refers to 
Faculty ofMedicine and Surgery,handedness i.e. being left or right handed. 
University ofMalta,Enantiomers are mirror images and can be 
Msidadistinguished from the way they rotate polarized 
light, hence the (+)/(-) or (d)/(1) nomenclature. 
I 
, 
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however in a chiral environment, such as the 
human body, their properties differ 1. It is not 
therefore surprising, that living organisms are 
able to discriminate between the two 
enantiomers, or left and right isomers of a chiral 
compound, and large differences occur between 
the biological responses they evoke. Selectivity 
of action is based on chemical- complem­
entariness between the bioactive agents and their 
specific molecular sites of action which may 
include enzymes, receptors, carriers2, just like a 
right-handed glove which will fit the right hand 
perfectly but is uncomfortable on the left. 
About 40% of synthetic drugs are chiral. Mason3 
has calculated that more than 80% of the 
synthetic chiral pharmaceuticals which appear in 
the United States Pharmacopoeia are 
administered as their racemates i.e. as equal 
mixtures of relatively 'active' and 'inactive' 
isomers. 
,ONCHIRAL 
~------- 6 .... old as a single isomer 
' , flSYNTHETIC < :;09
'ATLRAI SE\ . 	 . , re ~ClIIRAL52] 	 Id as a racemic mlxtu/ 	 517 so 
DRlJ(;S 'O'CHIRAL 
------- 799 ~ , ~Ie isomeo­\ S .... 	 'TIIETf{~ ~"'Old6~S a Sin 
1327 ~ CHIRAL 
S2X sold as a racemic miXlure 
467 
Figure III - Chirality of drugs: 
their application as single isomers or racemates 3.24.25 
This may be because it is easier to synthesize 
mixtures of enantiomers rather than the pure 
forms themselves. The inactive form, however, 
may not be a passive component of the drug 
mixture. It may be an agonist, or an antagonist, 
or it may have actions on other receptors, 
resulting in either unwanted side effects or 
contributing to overall drug efficacy. In addition, 
its metabolites may also be active or toxic. 
HISTORY 
"All artificial bodies and all minerals have 
superimposable images. Opposed to these are 
nearly all organic substances which play an 
important role in plant and animal life. These 
are asymmetric, and indeed have the kind of 
symmetry in which the image is not 
superimposable with the object." 
- Louis Pasteur, 1890 4 
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The existence of optical isomerism has been 
known since the first half of the 19th century. In 
1815, Jean-Baptiste Biot discovered optical 
activity and in 1848, Louis Pasteur isolated, for 
the first time in history, a pair of non-· 
superimposable mirror-image crystal forms 
which liberated (d)- and (1)- tartaric acid 4. In the 
1930's, British pharmacologist, Arthur R. 
Cushing, demonstrated substantial differences 
between the pharmacological properties of 
atropine, or racemic hyoscyamine, a cholinergic 
antagonist, and (1)- hyoscyamine. During the 
1950's, the importance of stereochemical 
considerations in medicinal chemistry and drug 
design was consistently emphasized by Arnold 
Beckett and Alan Casey in their classical studies 
on synthetic opiate type narcotics. However in 
the 1960's, the addition to the therapeutic 
armaentarium of novel synthetic drugs was 
invariably always in the racemic form 5. 
Perhaps the most tragic example is thalidomide. 
This drug was marketed during the 1960's as a 
sedative, and it was widely used by pregnant 
women, many of whom later gave birth to 
deformed children. Thalidomide was admin­
istered as a racemic mixture of its two optical 
isomers. Too late, did following research show 
that it was only the sinistral (-)-isomer, and not 
the (+)-isomer, which had a teratogenic effect on 
rat embryos, producing the same birth defect as 
those of the thalidomide children in the early 
1960's 6. 
Questions of whether clinical efficacy and safety 
are greater in one member of a stereoisomeric 
pair of drugs are now being asked, and tem1S 
such as isomeric ballast7 and composite chiral 
drugs (CCDs)8 have now become commonplace. 
TODAY 
Present day medical curricula deal with 
stereochemistry as something to be mentioned 
only when dealing with the biochemistry of 
amino acids and sugars. Few teaching and 
reference books even mention stereochemistry 
and its significance 2. 
In current research, the rapid emergence of 
published data regarding drug enantiomers is 
indicating strongly that studies on individual 
,enantiomers should be quantitated individually 
for a number of reasons: 
• 	 the kinetics of drug enantiomers often differ, 
leading to interindividual variation in the 
plasma ratio of the enantiomers 
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• 	 the phannacological properties of drug 
enantiomers are often different 
• 	 the technology to routinely separate and 
quantitate drug enantiomers is rapidly 
advancing 9. 
EVALUATION OF 
STEREOPHARMACOLOGICAL 
VARIATIONS IN SOME 
DRUG RACEMATES 
Various studies have now been reported in the 
literature about differences in the 
phannacokinetic and phannacological activity of 
racemic drugs. Some drugs are already being 
marketed as the pure enantiomer e.g. (-)­
naproxen, a non-steriodal anti-inflammatory 
drug; (+)-timolol, a beta-adrenoreceptor 
blocking agent; (d)-methyldopa, an 
antihypertensive and (d)-dextromethorphan, an 
antitussive. 10 
9ne of the first examples reported in the 
literature of stereoselective drug metabolism in 
man, was that of the hypnotic drug hexobarbital. 
When the separate enantiomers were 
administered, a very clear central depressant 
effect was seen after the (S)-hexobarbital, but not 
the (R)-hexobarbital. The total clearance of (S)­
hexobarbital was found to be only about one 
third of the (R)-hexobarbital, thus plasma 
concentrations for the (S)-hexobarbital were 
higher and half-life longer than for the (R)­
isomer. I I 
It has been reported that it is (d)-propranolol 
which acts as the beta-adrenoreceptor agent, but 
both stereoisomers contribute to its local 
anaesthetic and histamine releasing action. 12 (d)­
Ketamine is predominantly a hypnotic and an 
analgesic, whereas the (I)-isomer is the main 
source of its unwanted side-effects. 13 The 
therapeutic index of disopyramide could be 
improved by eliminating the (-)-isomer. This 
enantiomer is a less potent anti-arrhythmic then 
the (+)-form, and it is mostly responsible for the 
heart failure precipitated by administration of the 
racemic drug, through its marked . negative 
inotropic effect. Sotalol is another example of an 
anti-arrhythmic agent where the use of the 
racemate is inappropriate. There is excellent 
animal evidence showing that the (-)-isomer is 
devoid of beta-blocking activity.14 
Care must be exerted if decisions are taken to 
change from a racemate to an isomer. Although 
the (S)-isomer of warfarin is about 3-5 times as 
potent as its antipode, switching from the 
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racemate to the (S)-isomer, would necessitate a 
reduction in the dose. There would be no change 
in therapeutic index and this would precipitate a 
specific set of potential drug interactions. 15 To 
the contrary, the greater. intrinsic anti­
inflammatory potency of (S)-ibuproJen is 
compensated to some extent when using the 
racemate by metabolic inversion of the less 
active (R)-form and in fact approximately 60% of 
an oral dose of (R)-ibuprufcn is inverted to the 
(S)-enantiomer. 16 
After oral administration of metoprolol, even 
though the plasma elimination half-lives of the 
enantiomers are similar, plasma concentrations of 
(S)-metroprolol were 67% higher than those of 
(R)-metoprolol. Clinically, this means that with 
equal plasma concentrations of metoprolol, a 
greater degree of beta blockage will be observed 
in extensive metabolisers than in slower 
metabolisers.'7 Research has also been carried 
out on the influence of stereoisomeric factors in 
the pharmacokinetics of chiral drugs used in the 
extremes of age such as the elderly. 18 
These are just a few examples of the large 
number of research papers being published in the 
specialised journals. A number of excellent 
reviews and textbooks are now available on the 
subject of drug chirality. 
REGULATIONS 
The regulatory authorities are beginning to 
respond to the scientific and clinical maelstrom 
concerning the issue of drug racemates and 
enantiomers. 19 In the United States, the Federal 
Drug Agency, FDA, has an ongoing discussion 
with the phannaceutical industry, which is likely 
to lead to the promulgation of guidelines and a 
policy statement has just been published.20 In 
Europe, the European Community Committee for 
Proprietary Medicinal Products has issued a draft 
guideline statement on isomerism for inclusion in 
its "Notice to Applicants".21 If adopted, as looks 
likely, new submissions for drugs with chiral 
centres will have to provide information, 
interalia, on the following points: 
• 	 isomer ratio and batch to batch consistency; 
• 	 a discussion of the toxicological and 
pharmacological properties of the isomers; 
• 	 enantiomer-specific metabolism and kinetics; 
• 	 the extrapolation of preclinical data 
(particularly if species difference occur in the 
handling of stereoisomers); 
• 	 a discussion of possible clinical problems 
that may arise in relation to stereoisomers. 
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In Japan, the health authorities, in meetings with 
the phannaceutical industry, have explained their 
requirements in the context of the registration of 
a racemic mixture or optical isomer22. Basically, 
for a racemic mixture, information will be 
required for its toxicity, phannacology (efficacy 
and general), the disposition of each isomer and 
on the extent of the interconversion between the 
two isomeric forms. Lastly, information will be 
required for isomer purity: if one of the isomers 
constitutes a major "impurity", then this will have 
to be fully studied in terms of toxicity, 
phannacology and disposition 5. 
CONCLUSION 
Should chiral drugs be used as a single isomer? 
Perhaps it is wrong to start a witch hunt for 
racemic drugs which are already marketed23, but 
it can be predicted that a full clinical study of the 
phannacological and toxicological effects of both 
ertimtiomers of any new chiral drug, may be 
required soon, in order to obtain authorization for 
marketing the drug as a racemic mixture. 
The production of optically active drugs, in place 
of racemates, does not seem to be a profitable 
venture. It would increase production costs, and 
to state bluntly that racemic drugs contain a 50% 
impurity, is a gross simplification. Many 
scientific factors such as synthetic pathways, 
formulation and stability problems, should be 
taken into account. These factors require a 
wealth of phannacokinetic and phannaco­
dynamic information which is not always 
available. Decisions on whether the racemate or 
enantiomer is developed for marketing should, in 
one's opinion, be taken on a case by case basis, 
maintaining proper ethical and scientific 
attitudes. 
Arguments for marketing drugs 
as pure enantiomers 
• Improved less complex and more selective 

pharmacological profile 

• Better therapeutic . index 
• 	Less complex pharmacokinetics 
• 	Less complex plasma concentration-response 

relationships particularly in relation-to 

therapeutic drug monitoring 

Arguments against marketing drugs 
as pure enantiomers 
• Cost of development 
• Cost of production 
FIgure IV • Enantiomers or racemates? 26 
Other factors have to be taken into account. 
These include feasibility and cost of 
stereospecific enantiomer synthesis or separation 
and the quality control of isomeric purity. All in 
all, this probably argues for some sort of 
'decision tree' approach to the issue. 
comp/el 
ab.\CnI 
~o 
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FIgure V • Proposed logical scheme addressing the 
question: should chiral drugs be used as a single isomer? 23 
This would incorporate factors such as 
phannacological and toxicological properties of 
the enantiomers, phannacokinetic properties, 
interactive potential, feasibility and cost of 
production, quality control criteria and 
'marketing edge' 5. Some drugs are already being 
developed as the pure enantiomers from existing 
composite chiral drugs with still valid patents. 
These include (S)-atenolol, (R)-salbutamol and 
(S)-fluriprofen 8. 
Some in the medical community may find all this 
somewhat daunting and have accused the 
phannaceutical industry of stereophobia 14 . 
Nevertheless, the re-realization of the importance 
of stereochemistry in phannacologyhas an 
important contribution to make to the 
development and use of safer and more effective 
medicines. Drug therapy can only gain from 
such fruitful discussions from the continual 
assessment of 'looking glass drugs' and it is 
useful to remember that a basic rule in science is 
"non capability or impossibility to do things the 
proper way is no excuse to do them the wrong 
way" 2. 
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